Introducing XTANDI enzalutamide capsules A New Therapeutic Option

Introducing XTANDI® (enzalutamide) capsules A New Therapeutic Option for Patients with Metastatic Castration-Resistant Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway Jose Edson Pontes, MD Professor of Urologic Oncology, Wayne State University Karmanos Cancer Center Wayne State University Detroit, MI XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 1

Speaker Disclosures This is a promotional program sponsored by Astellas Pharma US, Inc. and Medivation, Inc. , and the speakers have entered into a written agreement for their services in connection with this program Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 2

Prostate Cancer Disease Burden It is estimated that #1 #2 most frequently diagnoseda solid tumor in men 1 leading cause of cancer deaths in men 1 1 in 6 men in the United States will be diagnosed with prostate cancer during their lifetime 1 28, 170 deaths Over 241, 000 new cases of prostate cancer are estimated to occur in the United States during 20121 5 yr Overall Survival 2 Localized Disease: 100% Metastatic Disease: 28% estimated to occur in the US in 20121 a Excluding non-melanoma skin cancer. 1. American Cancer Society. Cancer Facts & Figures 2012. Available at: http: //www. cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941. pdf. Accessed August 19, 2012. 2. National Cancer Institute. Surveillance Epidemiology and End Results. http: //seer. cancer. gov/statfacts/html/prost. html Accessed August 31, 2012. 012 I-076 -6349 -2 9/12 3

Prostate Cancer Disease Continuum First-line Hormonal Therapy Second-line Therapy Chemotherapy Immunotherapy Death PSA Level Local Therapy Post-Chemotherapy Time Castration Sensitive 1 Castration Resistant 1 Androgen Receptor Signaling 2 1. Higano CS. Chapter 28 in: Figg WD, et al. (eds. ), Drug Management of Prostate Cancer, 321 DOI 10. 1007/978 -1 -60327 -829 -4_28, ©Springer Science+Business Media, LLC 2010. 2. Schweizer MT, et al. Ther Adv Urol. 2012; 4(4): 167 -178. 012 I-076 -6349 -2 9/12 4

Androgen Receptor Signaling Pathway Is a Key Driver of Prostate Tumor Cell Growth PROSTATE CANCER CELL Androgen production 1 ANDROGEN Androgen binds to the androgen receptor (AR)1 Nuclear translocation of activated AR 1 ANDROGEN RECEPTOR DNA binding, transcription, and tumor cell growth 1 CELL CYTOPLASM CELL NUCLEUS 1. Harris WP, et al. Nature Rev Clin Pract Urol. 2009; 6(2): 76 -85. 2. Hu R, et al. Expert Rev Endocrinol Metab. 2010; 5(5): 753 -64. Although androgen dependence can decrease over time, castration-resistant prostate cancer remains dependent on androgen receptor signaling for growth 1, 2 012 I-076 -6349 -2 9/12 5

Continued AR Signaling in CRPC is Driven Through Aberrant Mechanisms • • Alternative m. RNA variations due to altered splicing found in CRPC 1 Splice variants can be constitutively active • Mutations may allow activation of AR by other ligands (eg, progesterone, estrogen, prednisone) Activation by non-androgens Activation without androgen • • AR amplification occurs in 50 -85% of CRPC cases Overexpression of AR results in increased sensitivity to reduced levels of androgen • Overexpression of ARa Cross-talk between growth factor signaling pathways can stimulate AR activity Signaling cross-talk MAPK PI 3 K AKT CELL NUCLEUS a Multiple CYTOPLASM AR co-activators are also overexpressed in CRPC. 1. Hu R, et al. Expert Rev Endocrinol Metab. 2010; 5(5): 753 -64; 2. Heinlein CA, et al. Endocr Rev. 2004; 25(2): 276 -308; 3. Watson PA, et al. Proc Natl Acad Sci. 2010; 107(39): 16759 -65; 4. Hu R, et al. Cancer Res. 2009; 69: 16 -22. 012 I-076 -6349 -2 9/12 6

Introduction to XTANDI (enzalutamide) capsules XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 77

Discovery of XTANDI • In the 1990 s, it was believed that castration-resistant prostate cancer (CRPC) progression was no longer dependent on hormones; therefore nonhormonal therapies were evaluated 1 • Recently, it has become clear that CRPC remains hormone dependent 1 – In preclinical models of CRPC, resistance to androgen deprivation therapy was associated with increased expression of the androgen receptor and increased sensitivity of the androgen receptor to low levels of androgen • XTANDI was selected from a library of compounds for its ability to inhibit androgen receptor signaling in cells over-expressing the androgen receptor 2 • In pre-clinical studies, XTANDI was shown to work within prostate cancer cells to induce cell death, decrease proliferation, and decrease tumor volume 3 1. Schweizer MT, et al. Ther Adv Urol. 2012; 4(4): 167 -178; 2. Tran, et al. Science 2009; 324(5928): 787 -790; 3. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 8

In Preclinical Studies, XTANDI Targets Multiple Steps in the Androgen Receptor Signaling Pathway in The Tumor Cell PROSTATE CANCER CELL XTANDI has not demonstrated agonist activity 1, 2 XTANDI 3 ANDROGEN RECEPTOR CELL CYTOPLASM X Competitively inhibits androgen binding to androgen receptors Inhibits androgen receptor nuclear translocation X Inhibits androgen receptor interaction with DNA X Induces cell death, decreases proliferation, and decreases tumor volume* CELL NUCLEUS * Based on preclinical data 1. Tran C, et al. Science 2009; 324(5928): 787 -790. 2. Jung ME, et al. J Med Chem. 2010; 53(7): 2779 -96. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 3. 012 I-076 -6349 -2 9/12 9

AFFIRM: A Phase 3, Global, Placebo. Controlled, Randomized Study of XTANDI in Patients With m. CRPC Who Previously Received Docetaxel Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 10 10

Pivotal Phase 3 Trial: Study Design Study population (N = 1199) Randomized 2: 1 m. CRPC Prior docetaxel therapy XTANDI (n = 800) Primary Endpoint: 160 mg po daily Overall Survival Placebo (n = 399) Secondary endpoints included 2: • Patients were allowed, but not required, to take glucocorticoids • XTANDI was taken with or without food 2 • All patients continued androgen deprivation therapy • Patients with predisposing factors for seizure were excluded from the trial • • • Radiographic progression-free survival Time to PSA progression Time to first skeletal-related event Quality of life Soft tissue objective response rate Measure of PSA response • Patients continued treatment until evidence of radiographic progression, a skeletal-related event, or clinical progression and initiation of new systemic antineoplastic treatment; unacceptable toxicity; or withdrawal 1. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. 2. Scher HI, et al. N Engl J Med. 2012; 367: 1187 -97. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 11

In the Pivotal Phase 3 Trial: Baseline Characteristics Were Balanced Between The Treatment Arms XTANDI (n = 800) Placebo (n = 399) 69 (41− 92) 69 (49− 89) 5. 9 6. 0 PSA (median ng/m. L) 107. 7 128. 3 Lactate Dehydrogenase (median IU/L) 209. 0 213. 0 Gleason score at initial diagnosis ≤ 7 >7 49. 6% 50. 4% 47. 6% 52. 4% ECOG Performance Status 2 8. 8% 8. 0% Mean Brief Pain Inventory Score ≥ 4 28. 3% 28. 8% Age (median in years, range) Years since diagnosis (median) ECOG = Eastern Cooperative Oncology Group. 1. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. 2. Scher HI, et al. N Engl J Med. 2012; 367: 1187 -97. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 12

In the Pivotal Phase 3 Trial: Baseline Characteristics Were Balanced Between The Treatment Arms (continued) XTANDI (n = 800) Placebo (n = 399) 92. 2% 91. 5% 37. 8% 70. 9% 68. 9% 15. 4% 11. 6% 14. 8% 8. 5 8. 0 Treated with at least 2 prior hormonal therapies 91. 8% 91. 2% Prior use of bicalutamide 83. 6% 87. 0% Bone Disease > 20 Bone Lesions Soft Tissue Disease Visceral lung Visceral liver Median number of prior docetaxel cycles 1. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. 2. Scher HI, et al. N Engl J Med. 2012; 367: 1187 -97. 3. Data on File, Medivation Inc. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 13

Efficacy Results From the Pivotal Phase 3 Trial Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 14 14

Hazard Ratios • Hazard ratios are the preferred method of many researchers to assess survival 1 • Hazard ratio describes how often a particular event happens in one group compared to how often it happens in another group, over time 2 • A hazard ratio is a value with no dimensions (eg, time)1 rate of death per at-risk population in XTANDI arm over time Hazard Ratio = = 0. 63 3 rate of death per at-risk population in placebo arm over time • A lower hazard ratio means a bigger difference between groups 1 1. Blagoev K, et al. Nat Rev Clin Oncol. 2012 Jan 31; 9(3): 178 -83. 2. NCI Dictionary of Cancer Terms. Accessed October 2, 2012 at http: //www. cancer. gov/dictionary? cdrid=618612. 3. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 15

XTANDI Reduced Risk of Death By 37% Number of Deaths (%) Median Survival (months) (95% CI) P-valuea Hazard Ratio (95% CI)b XTANDI (n = 800) Placebo (n = 399) 308 (38. 5%) 212 (53. 1%) 18. 4 (17. 3, NR) 13. 6 (11. 3, 15. 8) <0. 0001 0. 63 (0. 53, 0. 75) a P-value is derived from a log-rank test stratified by baseline ECOG performance status score (0 -1 vs. 2) and mean baseline pain score (BPI-SF score < 4 vs. ≥ 4) b Hazard Ratio is derived from a stratified proportional hazards model. Hazard ratio <1 favors XTANDI • *NR: Not reached and therefore unable to calculate • The upper limit of the 95% confidence interval was not calculable because an insufficient number of deaths had occurred by the time point for assessment. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 16

Overall Survival 100 4. 8 month difference P <0. 0001 XTANDI 18. 4 months 80 95% CI (17. 3, not reached) Overall Survival (%) 60 40 Placebo 13. 6 months 20 95% CI (11. 3, 15. 8) XTANDI demonstrated a statistically significant improvement in median overall survival vs placebo 0 0 3 6 9 12 Months 15 18 21 24 Patients at Risk (n): XTANDI 800 775 701 627 400 211 72 7 0 Placebo 399 376 317 263 167 81 33 3 0 CI = confidence interval; HR = hazard ratio. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 17

Safety Results From the Pivotal Phase 3 Trial Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 18 18

Contraindication • Contraindication – XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action. XTANDI is not indicated for use in women. XTANDI is contraindicated in women who are or may become pregnant XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 19

Warning and Precaution: Seizure • • • Seven patients (0. 9%) out of 800 treated with XTANDI 160 mg once daily experienced a seizure – No seizures occurred in patients treated with placebo Patients experiencing seizure were permanently discontinued from therapy. All seizures resolved Seizures occurred from 31 to 603 days after initiation of XTANDI The safety of XTANDI in patients with predisposing factors for seizure is not known because these patients were excluded from the trial. These exclusion criteria included a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation, or the use of concomitant medications that may lower the seizure threshold Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 20

Adverse Reactions ≥ 2% Higher Frequency in the XTANDI Arm Compared to Placebo Arm Grade 1 -4 (%) Grade 3 -4 (%) XTANDI (n = 800) Placebo (n = 399) Asthenic conditionsa 50. 6 44. 4 9. 0 9. 3 Peripheral edema 15. 4 13. 3 1. 0 0. 8 Back pain 26. 4 24. 3 5. 3 4. 0 Arthralgia 20. 5 17. 3 2. 5 1. 8 Musculoskeletal pain 15. 0 11. 5 1. 3 0. 3 Muscular weakness 9. 8 6. 8 1. 5 1. 8 Musculoskeletal stiffness 2. 6 0. 3 0. 0 21. 8 17. 5 1. 1 0. 3 Hot flush 20. 3 10. 3 0. 0 Hypertension 6. 4 2. 8 2. 1 1. 3 General Disorders Musculoskeletal and Connective Tissue Disorders Gastrointestinal Disorders Diarrhea Vascular Disorders Adverse events graded according to NCI CTCAE version 4. 0 a Includes asthenia and fatigue. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 21

Adverse Reactions ≥ 2% Higher Frequency in the XTANDI Arm Compared to Placebo Arm (continued) Grade 1 -4 (%) Grade 3 -4 (%) XTANDI (n = 800) Placebo (n = 399) Headache 12. 1 5. 5 0. 9 0. 0 Dizzinessa 9. 5 7. 5 0. 5 Spinal cord compression and cauda equina syndrome 7. 4 4. 5 6. 6 3. 8 Paresthesia 6. 6 4. 5 0. 0 Mental impairment disordersb 4. 3 1. 8 0. 3 0. 0 Hypoesthesia 4. 0 1. 8 0. 3 0. 0 Upper respiratory tract infectionc 10. 9 6. 5 0. 0 0. 3 Lower respiratory tract and lung infectiond 8. 5 4. 8 2. 4 1. 3 Nervous System Disorders Infections and Infestations Adverse events graded according to NCI CTCAE version 4. 0 a c Includes dizziness and vertigo; b Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention; Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis; d Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 22

Adverse Reactions ≥ 2% Higher Frequency in the XTANDI Arm Compared to Placebo Arm (continued) Grade 1 -4 (%) Grade 3 -4 (%) XTANDI (n = 800) Placebo (n = 399) Insomnia 8. 8 6. 0 1. 8 1. 0 Anxiety 6. 5 4. 0 0. 3 0. 0 Hematuria 6. 9 4. 5 1. 8 1. 0 Pollakiuria 4. 8 2. 5 0. 0 Fall 4. 6 1. 3 0. 0 Non-pathological fractures 4. 0 0. 8 1. 4 0. 3 Pruritus 3. 8 1. 3 0. 0 Dry Skin 3. 5 1. 3 0. 0 3. 3 1. 3 0. 1 0. 3 Psychiatric Disorders Renal and Urinary Disorders Injury, Poisoning and Procedural Complications Skin and Subcutaneous Tissue Disorders Respiratory Disorders Epistaxis Adverse events graded according to NCI CTCAE version 4. 0 XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 23

Similar Rates of Overall Grade 3 and Higher Adverse Events Between Arms 8. 3 months median duration of treatment with XTANDI vs 3. 0 months with placebo The rate of Grade 3 and higher AEs with XTANDI was comparable to placebo 47% XTANDI AEs ≥ Grade 3 Placebo 0 10 53% 20 30 40 50 60 70 80 90 100 Percent of Patients (%) AE = adverse event. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 24

Similar Rates of Discontinuation Between Arms 8. 3 months median duration of treatment with XTANDI vs 3. 0 months with placebo The discontinuation rate due to AEs with XTANDI was comparable to placebo XTANDI D/C due to AEs Placebo 0 10 16% 18% 20 30 40 50 60 70 80 90 100 Percent of Patients (%) The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0. 9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients D/C = discontinuation. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 25

Hepatic Laboratory Abnormalities Percent of Patients* (%) XTANDI (n = 800) Placebo (n = 399) ALT elevation (Grade 1 -4) 10% 18% ALT elevation (Grade 3 -4) 0. 3% 0. 5% 3% 2% Laboratory Abnormalities Bilirubin elevation (Grade 1 -4) ALT = alanine aminotransferase *XTANDI has not be evaluated in patients with baseline severe hepatic impairment (Child-Pugh C). XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 26

Hematologic Laboratory Abnormalities Percent of Patients (%) XTANDI (n = 800) Placebo (n = 399) Neutropenia (Grade 1 -4) 15% 6% Neutropenia (Grade 3 -4) 1% 0% 0. 5% 1% Laboratory Abnormalities Thrombocytopenia (Grade 3 -4) • The incidence of Thrombocytopenia (Grade 1 -4) was similar in both arms XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 27

Additional Safety Considerations In the randomized clinical trial: • 1. 0% of patients treated with XTANDI vs 0. 3% on placebo died from infections or sepsis – Infection-related serious adverse events were reported in approximately 6% of the patients on both treatment arms • 4. 6% of patients treated with XTANDI vs 1. 3% on placebo experienced falls or injuries related to falls – Falls were not associated with loss of consciousness or seizure – Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas • 1. 6% of patients treated with XTANDI were reported to have (Grade 1 -2) hallucinations vs 0. 3% on placebo – Among these patients, the majority were on opioid-containing medications at the time of the event XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 28

Dosing and Administration, and Drug Interactions Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 29 29

XTANDI Dosing and Administration • XTANDI is administered as 160 mg (four 40 mg capsules) • XTANDI can be taken with or without food • Patients were allowed, but not required, to take glucocorticoids – In the clinical trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 30

XTANDI Dosing and Administration (continued) • Each capsule should be swallowed whole. Patients should not chew, dissolve, or open the capsules • If a dose of XTANDI is missed, inform patients that they should take it as soon as they remember – If patients forget to take the dose for the whole day, then they should take their normal dose the next day – Patients should not take more than their prescribed dose per day • XTANDI should be stored at 20°C to 25°C (68°F to 77°F) in a dry place with the container tightly closed – Excursions permitted from 15°C to 30°C (59°F to 86°F) XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 31

XTANDI Dose Adjustments • No dose adjustment of XTANDI is necessary for: – Patients with mild to moderate hepatic impairment – Patients with mild to moderate renal impairment • XTANDI has not been evaluated in patients with baseline severe hepatic impairment (Child-Pugh C), patients with severe renal impairment (Cr. Cl <30 m. L/min), or endstage renal disease XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 32

Drug Interactions Effect of other drugs on XTANDI Effect of XTANDI on other drugs Co-administered drugs CYP 3 A 4 substrates (eg, midazolam) CYP 2 C 9 substrates (eg, S-warfarin)a CYP 2 C 19 substrates (eg, omeprazole) CYP 2 C 8 substrates (eg, pioglitazone) Recommendation Avoid concomitant use of substrates with a narrow therapeutic index No dose adjustment Co-administered drugs Recommendation CYP 2 C 8 inhibitor (eg, gemfibrozil) Reduce XTANDI doseb CYP 3 A 4 inhibitor (eg, itraconazole) No initial dose adjustment b Avoid strong CYP 2 C 8 inhibitors. If co-administration is necessary, reduce the XTANDI dose to 80 mg once daily. a If XTANDI is coadministered with warfarin, conduct additional INR monitoring. CYP = cytochrome P 450. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 33

XTANDI Summary 18. 4 -month median OS with XTANDI vs 13. 6 months with placebo (P < 0. 0001) • • • 37% reduction in risk of death (HR = 0. 63 [95% Cl, 0. 53, 0. 75]) XTANDI can be taken with or without food Patients were allowed, but not required, to take glucocorticoids – • • In the clinical trial, 48% of patients in the XTANDI arm and 46% of patients in the placebo arm received glucocorticoids Oral, once-daily dosing The rate of grade 3 and higher adverse reactions with XTANDI was 47% vs placebo at 53% Seven patients (0. 9%) out of 800 treated with XTANDI 160 mg once daily experienced a seizure. No seizures occurred in patients treated with placebo The most common adverse drug reactions (≥ 5%) were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules 012 I-076 -6349 -2 9/12 34

Q&A © 2012 Astellas Pharma US, Inc. All rights reserved. Printed in USA. XTANDI is a registered trademark of Astellas Pharma Inc. Astellas and the flying star logo are trademarks of Astellas Pharma US, Inc. Please see accompanying Full Prescribing Information for complete safety information for XTANDI (enzalutamide) capsules. 012 I-076 -6349 -2 9/12 35 35